Zebra Capital Management LLC trimmed its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 37.3% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,783 shares of the company’s stock after selling 6,421 shares during the quarter. Zebra Capital Management LLC’s holdings in Henry Schein were worth $783,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in HSIC. Squar Milner Financial Services LLC acquired a new position in shares of Henry Schein during the 2nd quarter worth about $120,000. Piedmont Investment Advisors LLC acquired a new position in shares of Henry Schein in the 2nd quarter valued at approximately $130,000. Fuller & Thaler Asset Management Inc. grew its position in shares of Henry Schein by 57.1% in the 2nd quarter. Fuller & Thaler Asset Management Inc. now owns 2,200 shares of the company’s stock valued at $160,000 after purchasing an additional 800 shares during the period. BerganKDV Wealth Management LLC acquired a new position in shares of Henry Schein in the 2nd quarter valued at approximately $203,000. Finally, Quest Investment Management LLC acquired a new position in shares of Henry Schein in the 2nd quarter valued at approximately $214,000. 96.65% of the stock is owned by institutional investors and hedge funds.
Shares of HSIC stock opened at $86.97 on Tuesday. The company has a quick ratio of 0.68, a current ratio of 1.29 and a debt-to-equity ratio of 0.34. The firm has a market cap of $13.02 billion, a P/E ratio of 24.10, a price-to-earnings-growth ratio of 2.45 and a beta of 0.97. Henry Schein, Inc. has a twelve month low of $62.56 and a twelve month high of $90.52.
HSIC has been the topic of a number of analyst reports. Zacks Investment Research upgraded Henry Schein from a “hold” rating to a “buy” rating and set a $85.00 price objective on the stock in a research note on Tuesday, July 10th. BidaskClub raised Henry Schein from a “hold” rating to a “buy” rating in a report on Wednesday, June 13th. Leerink Swann set a $100.00 target price on Henry Schein and gave the stock a “buy” rating in a report on Tuesday, August 7th. Barrington Research reaffirmed a “buy” rating and issued a $92.00 price objective on shares of Henry Schein in a report on Tuesday, August 7th. Finally, Craig Hallum upped their price objective on Henry Schein from $83.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Henry Schein has a consensus rating of “Hold” and a consensus price target of $85.06.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Further Reading: What is a stock split?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.